疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2646人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720994, encodeId=16a41e2099498, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析, objectType=article, longId=207743, objectId=d89920e7436b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89920e7436b, replyNumber=0, likeNumber=76, createdTime=2021-08-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89920e7436b, moduleTitle=Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89920e7436b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721038, encodeId=f0681e2103899, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Am J Psychiatry：重复使用氯胺酮治疗慢性创伤后应激障碍的疗效和安全性如何？, objectType=article, longId=213246, objectId=c7ab2132466a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ab2132466a, replyNumber=0, likeNumber=74, createdTime=2021-09-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ab2132466a, moduleTitle=Am J Psychiatry：重复使用氯胺酮治疗慢性创伤后应激障碍的疗效和安全性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ab2132466a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720974, encodeId=905e1e20974aa, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, objectType=article, longId=202999, objectId=8918202999cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8918202999cd, replyNumber=0, likeNumber=61, createdTime=2021-07-25, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8918202999cd, moduleTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8918202999cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721060, encodeId=23da1e2106067, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, objectType=article, longId=215273, objectId=4e602152e3e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e602152e3e8, replyNumber=0, likeNumber=72, createdTime=2022-07-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e602152e3e8, moduleTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e602152e3e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721035, encodeId=350c1e21035be, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=78, createdTime=2022-05-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721042, encodeId=a5171e21042ff, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=75, createdTime=2021-06-29, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720982, encodeId=ad351e20982f7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性, objectType=article, longId=205423, objectId=1d0e20542306, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0e20542306, replyNumber=0, likeNumber=60, createdTime=2021-07-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0e20542306, moduleTitle=Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0e20542306)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721010, encodeId=fd051e2101040, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性, objectType=article, longId=210895, objectId=1c9e21089525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c9e21089525, replyNumber=0, likeNumber=59, createdTime=2021-06-10, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c9e21089525, moduleTitle=Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c9e21089525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721053, encodeId=e5d61e21053db, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=98, createdTime=2022-05-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721014, encodeId=b07c1e21014cf, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, objectType=article, longId=211042, objectId=63df21104261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df21104261, replyNumber=0, likeNumber=113, createdTime=2022-01-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df21104261, moduleTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df21104261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720968, encodeId=e3351e209682c, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验, objectType=article, longId=200658, objectId=72552006581b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72552006581b, replyNumber=0, likeNumber=85, createdTime=2020-12-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72552006581b, moduleTitle=JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72552006581b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721037, encodeId=86231e21037d2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究, objectType=article, longId=213227, objectId=2d7321322eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d7321322eb9, replyNumber=0, likeNumber=72, createdTime=2021-10-27, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d7321322eb9, moduleTitle=Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d7321322eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721016, encodeId=458b1e21016d5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, objectType=article, longId=211073, objectId=73fa2110e321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fa2110e321, replyNumber=0, likeNumber=128, createdTime=2021-11-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fa2110e321, moduleTitle=Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73fa2110e321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720963, encodeId=c4bd1e209630f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Craniofac Surg：颌下经导管灌注麻醉在颌下腺手术中的疗效和安全性, objectType=article, longId=199022, objectId=cef0199022bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cef0199022bf, replyNumber=0, likeNumber=78, createdTime=2021-03-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cef0199022bf, moduleTitle=J Craniofac Surg：颌下经导管灌注麻醉在颌下腺手术中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cef0199022bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720985, encodeId=45a11e20985c7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol：新型抗CTLA4抗体Quavonlimab联合派姆单抗一线治疗NSCLC的疗效和安全性, objectType=article, longId=205893, objectId=d5d12058931d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d12058931d, replyNumber=0, likeNumber=93, createdTime=2021-03-23, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d12058931d, moduleTitle=Ann Oncol：新型抗CTLA4抗体Quavonlimab联合派姆单抗一线治疗NSCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5d12058931d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721012, encodeId=7ff21e2101251, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Bipolar Disord：卡利拉嗪治疗双相I型抑郁症的疗效和安全性, objectType=article, longId=210952, objectId=cd71210952b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd71210952b8, replyNumber=0, likeNumber=59, createdTime=2022-02-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd71210952b8, moduleTitle=Bipolar Disord：卡利拉嗪治疗双相I型抑郁症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd71210952b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720984, encodeId=e9221e209840a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：度伐单抗+曲美单抗±立体定向体部放疗治疗复发性小细胞肺癌的疗效和安全性, objectType=article, longId=205702, objectId=9b3d205e0248, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3d205e0248, replyNumber=0, likeNumber=65, createdTime=2021-02-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3d205e0248, moduleTitle=J Immunother Cancer：度伐单抗+曲美单抗±立体定向体部放疗治疗复发性小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3d205e0248)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721006, encodeId=0e671e2100643, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, objectType=article, longId=210513, objectId=1f42210513fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f42210513fc, replyNumber=0, likeNumber=85, createdTime=2022-02-25, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f42210513fc, moduleTitle=J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f42210513fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720964, encodeId=10221e2096427, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性, objectType=article, longId=199169, objectId=79d81991691e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79d81991691e, replyNumber=0, likeNumber=81, createdTime=2021-07-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79d81991691e, moduleTitle=Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79d81991691e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720969, encodeId=1e8e1e2096935, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Matern Fetal Neonatal Med：口服扑热息痛VS口服布洛芬治疗早产儿动脉导管未闭的疗效和安全性, objectType=article, longId=201694, objectId=9c0d2016946f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0d2016946f, replyNumber=0, likeNumber=63, createdTime=2021-06-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0d2016946f, moduleTitle=J Matern Fetal Neonatal Med：口服扑热息痛VS口服布洛芬治疗早产儿动脉导管未闭的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0d2016946f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Gastroenterology H: 5-HT-4受体激动剂米沙必利治疗肠易激综合征患者的疗效和安全性分析

2021-08-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Am J Psychiatry：重复使用氯胺酮治疗慢性创伤后应激障碍的疗效和安全性如何？

2021-09-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性

2021-07-25

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性

2022-07-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2022-05-17

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-06-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性

2021-07-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性

2021-06-10

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2022-05-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性

2022-01-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验

2020-12-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究

2021-10-27

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：吉西他滨+白蛋白结合型紫杉醇对比FOLFIRINOX一线治疗晚期胰腺癌疗效和安全性

2021-11-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Craniofac Surg：颌下经导管灌注麻醉在颌下腺手术中的疗效和安全性

2021-03-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol：新型抗CTLA4抗体Quavonlimab联合派姆单抗一线治疗NSCLC的疗效和安全性

2021-03-23

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Bipolar Disord：卡利拉嗪治疗双相I型抑郁症的疗效和安全性

2022-02-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：度伐单抗+曲美单抗±立体定向体部放疗治疗复发性小细胞肺癌的疗效和安全性

2021-02-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：3期| 来那度胺联合R-CHOP方案治疗ABC型DLBCL的疗效和安全性

2022-02-25

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res：ROCK-AKT双重抑制剂AT13148治疗实体瘤的疗效和安全性

2021-07-09

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Matern Fetal Neonatal Med：口服扑热息痛VS口服布洛芬治疗早产儿动脉导管未闭的疗效和安全性

2021-06-03

科室
- - 订阅+
  - 更多科室
工具
服务